1.
Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis
Pecher, A. C., Ach, K. R., Vogel, W., Henes, J. C.
Rheumatology (Oxford, England). 2022
Abstract
OBJECTIVES To assess the feasibility of reduced cyclophosphamide dosing in the setting of mobilization chemotherapy prior high dose chemotherapy and autologous stem cell transplantation in patients with systemic sclerosis. The primary end point was the occurrence of 'poor mobilization' when using different cyclophosphamide dosing. The second end point was to analyze potential risk factors for difficult stem cell mobilization in this cohort of patients with systemic sclerosis. METHODS This single-center study retrospectively reviewed 32 patients with systemic sclerosis who underwent autologous stem cell transplantation. We analyze the occurrence of 'poor mobilization' (defined as CD34+ progenitor cell count < 2 x 106/kg body weight, the use of increasing G-CSF dose, the use of plerixafor, or leukapheresis on > 2 consecutive days) in different cyclophosphamide mobilization regimens: We herein compared low dose (2x1-1.5g/m2) cyclophosphamide vs high dose (2x2g/m2) for mobilization. RESULTS Higher dosing of cyclophosphamide seems not to be beneficial regarding stem cell collection as there was no significant difference in stem cell yield between high dose and reduced dose cyclophosphamide (6.2 vs 5.2 x106/kg bodyweight after CD34+ enrichment). Furthermore, higher doses of cyclophosphamide might be associated with more side effects, this difference was however not statistically significant. Lower bodyweight and BMI (p< 0.001) as well as Rituximab pre-therapy (p< 0.05) and cardiac involvement (p< 0.01) might negatively impact stem cell collection independently from the chosen regimen. CONCLUSION Our data demonstrate that a reduced cyclophosphamide mobilization regimen seems to be feasible. Risk factors for poor mobilization might be low bodyweight, prior rituximab therapy and cardiac involvement.
2.
Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant
Jaime-Perez, J. C., Gomez-Galaviz, A. C., Turrubiates-Hernandez, G. A., Picon-Galindo, E., Salazar-Riojas, R., Mendez-Ramirez, N., Gomez-Almaguer, D.
Cytotherapy. 2020
Abstract
BACKGROUND AIMS Autologous hematopoietic stem cell transplantation (AHSCT) is an alternative for multiple sclerosis (MS) patients who do not respond to conventional treatment. Mobilization kinetics of CD34+ cells in MS patients has not been studied. METHODS Patients with MS mobilized with granulocyte colony-stimulating factor (G-CSF) and cyclophosphamide (Cy) were prospectively studied. Three counts of CD34+ cells were done in peripheral blood: at baseline before mobilization, at the start, and immediately at the end of apheresis. Complete blood counts were performed at the times of CD34+ cell counting. Standard statistical descriptive analysis of MS patients' salient features was performed, and after log 10 transformation of the data, Pearson test was performed to assess correlation between variables and CD34+ cell count. In addition, multiple linear regression of relevant data was carried out for multivariate analysis. RESULTS Data of 51 consecutive MS patients with median age of 48 (31-64) years were analyzed. The CD34+ cell count increased 26-fold after mobilization. During large volume leukapheresis (LVL), the number of CD34+ cells in peripheral blood increased from 51.29 CD34+/muL at the start to 62.3 CD34+/muL at the end. A negative correlation between CD34+ cell count after leukapheresis and age (r = -0.32, P = 0.02) was observed. Neither the CD34+ baseline count nor sex correlated with the CD34+ count in peripheral blood immediately at the end of apheresis. CONCLUSIONS Mobilization with G-CSF and Cy in MS patients resulted in effective CD34+ hematoprogenitors release from the bone marrow and in intra-apheresis recruitment.